Pliant Therapeutics Receives FDA Fast Track for PLN-101095 in Checkpoint-Resistant Solid Tumors
PLRX receives FDA Fast Track for oral PLN-101095 + Keytruda in ICI-refractory solid tumors. Cash runway into 2H 2028; data expected 2027.
/ 2 items
